The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Abaloparatide Effective for Osteoporosis & XmAb5871 Studied to Treat SLE

Abaloparatide Effective for Osteoporosis & XmAb5871 Studied to Treat SLE

March 30, 2016 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Subcutaneous Abaloparatide for Osteoporosis
Abaloparatide, a new synthetic peptide analog of hPTHrP (human parathyroid hormone-related protein), will soon be submitted for U.S. Food and Drug Administration (FDA) approval.1

You Might Also Like
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
  • Abaloparatide Appears Safe, Effective for Boosting BMD in Women 80 & Up
Also By This Author
  • Rheumatology Drug Updates: Infliximab Biosimilar Gets FDA Approval & More

[Editor’s note: Radius Health announced March 30 that it had submitted an NDA to the FDA for abaloparatide- SC 80 mcg.]

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

In Phase 3 clinical trials, subcutaneous abaloparatide significantly reduced incidents of vertebral fractures compared with placebo in postmenopausal women with osteoporosis.2 Additionally, the study’s secondary endpoints were also met. These endpoints included a statistically significant reduction in fracture rate in the adjudicated non-vertebral fracture subset of patients; a statistically significant reduction in the adjudicated clinical fracture group; and a statistically significant difference in the time to first incident, non-vertebral fracture in both the adjudicated non-vertebral fracture and the clinical fracture subsets of patients. Subcutaneous abaloparatide also achieved statistically significant increases in bone marrow density in the total hip, femoral neck and lumbar spine at Months 6, 12 and 18.

Transdermal abaloparatide is currently in Phase 2 clinical trials as a potential treatment of osteoporosis.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Steroid-Sparing Agent in Phase 2 Trials for Patients with Lupus
XmAb5871 is a first in class monoclonal antibody that targets CD19 and inhibits B cell function via FcγRIIb inhibition.3 In initial clinical trials, XmAb5871 inhibited B cell function without destroying these cells. The treatment demonstrated a promising effect in patients with rheumatoid arthritis (RA) and, potentially, inhibits systemic lupus erythematosus (SLE) B cell activation and humoral immunity.

This Phase 2 lupus study is a randomized, double-blind, placebo-controlled, multiple dose trial using a 1:1 randomization of XmAb5871 vs. placebo (N~90). Patients will discontinue immunosuppressive medications and receive a short intramuscular course of steroids. Then, participants will be randomized to receive placebo or active treatment XmAb5871 every two weeks for up to 12 infusions (six months). They will be examined for disease recurrence. The primary objective is to evaluate XmAb5871’s activity in maintaining lupus disease activity improvement. Safety tolerability, pharmacokinetics and pharmacodynamics (i.e., change in biomarkers) and immunogenicity will also be assessed.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Weisman R. Waltham’s Radius Health will seek federal OK for osteoporosis drug. Boston Globe. 2016 Mar 6.
  2. Radius Health Inc. Pipeline program status: Investigational drug product candidate Abaloparatide-SC. 2016.
  3. Xencor Inc. News release: Xencor initiates two phase 2 trials of XmAb5871 in IgG4-related disease and systemic lupus erythematosus. 2016 Mar 7.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates Tagged With: B cells, Lupus, monoclonal antibody, Osteoporosis, systemic lupus erythematosus (SLE), XmAb5871

You Might Also Like:
  • Abaloparatide May Boost BMD in Older Women with Osteoporosis
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis
  • Abaloparatide Appears Safe, Effective for Boosting BMD in Women 80 & Up
  • Abaloparatide-SC May Reduce Fractures for Osteoporosis & New FDA Safety Website

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.